| abstract |
The present invention provides a compound of formula (I): or an enantiomer, enantiomer mixture, or pharmaceutically acceptable salt thereof: [Formula I] (wherein the variables are as defined herein). The present invention provides pharmaceutical compositions comprising such compounds; and methods of using such compounds to treat a disease or condition mediated by mixed lineage leukemia 1 (MLL1). |